Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab in ME/CFS
2024-512500-19-00Phase 2Authorised
- Sponsor
- Helse Bergen
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of daratumumab in myalgic encephalomyelitis (ME), sponsored by Helse Bergen. Primary endpoint: Safety and tolerability. Planned start Jul 2024; status: authorised.
02
Drugs
daratumumab
03
Conditions
myalgic encephalomyelitis (ME)
Beyond the preview
Go deeper on 2024-512500-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512500-19-00.